Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 10/20 | 0.69 |
| ▸ | PPARA | Q07869 | 9/20 | 0.69 |
| ▸ | PPARG | P37231 | 6/20 | 0.69 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.58 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.58 |
| ▸ | PLA2G2A | P14555 | 5/20 | 0.57 |
| ▸ | ICMT | O60725 | 2/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5639523 | 0.89 | PPARD (0.60) | PPARDPPARAPPARGLTB4RLTB4R2 | |
| SCHEMBL8166905 | 0.88 | PPARD (0.74) | PPARDPPARAPPARGLTB4RLTB4R2 | |
| SCHEMBL13930965 | 0.86 | PPARD (0.77) | PPARDPPARAPPARGLTB4RLTB4R2 | |
| SCHEMBL8175031 | 0.84 | PPARD (0.72) | PPARDPPARAPPARGLTB4RLTB4R2 | |
| SCHEMBL13802400 | 0.83 | PLA2G2A (0.61) | PPARDPPARAPPARGPLA2G2AICMT | |
| SCHEMBL5802889 | 0.83 | PPARD (0.54) | PPARDPPARAPPARGLTB4RLTB4R2 | |
| SCHEMBL8174602 | 0.83 | PPARD (0.70) | PPARDPPARAPPARGLTB4RLTB4R2 | |
| SCHEMBL8183003 | 0.83 | ALDH1A1 (0.56) | PPARDPPARAPPARGPLA2G2AICMT | |
| SCHEMBL8299582 | 0.83 | PLA2G2A (0.78) | PPARDPPARAPPARGLTB4RLTB4R2 | |
| SCHEMBL4257266 | 0.82 | PPARD (0.69) | PPARDPPARAPPARGLTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | PPARD 1442/4885PPARA 744/4885PPARG 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.